FDA grants breakthrough designation to new sIBM drug

08/20/2013 | FoxNews.com

The investigational compound bimagrumab developed by Novartis and Morphosys for patients suffering from sporadic inclusion body myositis has received breakthrough therapy designation from the FDA. The status was given to the drug because it shows substantial improvement in treating the condition over existing drugs. The drug shows promise in blocking inhibitory molecules and supporting muscle growth.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA